Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117468 | 0.91 | MAPT (0.67) | SIGMAR1KDM4E | |
| SCHEMBL7512967 | 0.87 | DRD4 (0.77) | SIGMAR1POLBKDM4EGAAL3MBTL1 | |
| SCHEMBL242970 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL8188324 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL576868 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL2489199 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL1415730 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL1041303 | 0.87 | SIGMAR1 (1.00) | SIGMAR1LMNAPOLBACHEMC4R | |
| SCHEMBL16227001 | 0.87 | CCR3 (0.73) | SIGMAR1LMNAKDM4EHTTMEN1 | |
| SCHEMBL16225775 | 0.85 | TSHR (0.62) | SIGMAR1BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| EP-0816310-A2 | Scavenger assisted combinatorial process for preparing libraries of tertiary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | SIGMAR1 409/4885LMNA 3207/4885POLB 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.